5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Perforation O
or O
Fistula O
: O
Discontinue O
for O
tracheoesophageal O
fistula O
, O
grade O
4 O
fistula O
, O
or O
necrotizing O
fasciitis O
. O

( O
5.1 O
) O
* O
Arterial O
Thromboembolic O
Events O
( O
ATE O
) O
: O
Discontinue O
for O
severe O
ATE O
. O

( O
5.4 O
) O
* O
Venous O
Thromboembolic O
Events O
( O
VTE O
) O
: O
Discontinue O
for O
Grade O
4 O
VTE O
. O

( O
5.5 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Withhold O
if O
not O
medically O
controlled O
; O
resume O
once O
controlled O
. O

Discontinue O
for O
hypertensive O
crisis O
or O
hypertensive O
encephalopathy O
. O

( O
5.6 O
) O
* O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
: O
Discontinue O
. O

( O
5.7 O
) O
* O
Renal O
Injury O
and O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Discontinue O
for O
nephrotic O
syndrome O
. O

Withhold O
until O
less O
than O
2 O
grams O
of O
protein O
in O
urine O
. O

( O
5.8 O
) O
* O
Infusion O
Reactions O
: O
Decrease O
rate O
for O
infusion O
reactions O
. O

Discontinue O
for O
severe O
infusion O
reactions O
and O
administer O
medical O
therapy O
. O

( O
5.9 O
) O
* O
Embryo-fetal O
Toxicity O
: O
Advise O
females O
of O
potential O
risk O
to O
fetus O
and O
need O
for O
use O
of O
effective O
contraception O
. O

( O
5.10 O
, O
8.1 O
, O
8.3 O
) O
* O
Ovarian O
Failure O
: O
Advise O
females O
of O
the O
potential O
risk O
. O

( O
5.11 O
, O
8.3 O
) O
* O
Congestive O
Heart O
Failure O
( O
CHF O
) O
: O
Discontinue O
if O
CHF O
( O
5.12 O
) O
. O

5.1 O
Gastrointestinal O
Perforations O
and O
Fistulae O
Serious O
and O
sometimes O
fatal B-NonOSE_AE
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
occur O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

The O
incidence O
ranged O
from O
0.3 O
% O
to O
3 O
% O
across O
clinical O
studies O
, O
with O
the O
highest O
incidence O
in O
patients O
with O
a O
history O
of O
prior O
pelvic O
radiation O
. O

Perforation O
can O
be O
complicated O
by O
intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
, O
fistula B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
, O
and O
the O
need O
for O
diverting O
ostomies O
. O

The O
majority O
of O
perforations O
occurred O
within O
50 O
days O
of O
the O
first O
dose O
. O

Serious O
fistulae B-OSE_Labeled_AE
( O
including O
, O
tracheoesophageal O
, O
bronchopleural O
, O
biliary O
, O
vaginal O
, O
renal O
and O
bladder O
sites O
) O
occur O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

The O
incidence O
ranged O
from O
< O
1 O
% O
to O
1.8 O
% O
across O
clinical O
studies O
, O
with O
the O
highest O
incidence O
in O
patients O
with O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
majority O
of O
fistulae B-OSE_Labeled_AE
occurred O
within O
6 O
months O
of O
the O
first O
dose O
. O

Patients O
who O
develop O
a O
gastrointestinal B-OSE_Labeled_AE
vaginal I-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
may O
also O
have O
a O
bowel B-NonOSE_AE
obstruction I-NonOSE_AE
and O
require O
surgical O
intervention O
, O
as O
well O
as O
a O
diverting O
ostomy O
. O

Avoid O
Avastin O
in O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
have O
evidence O
of O
recto B-Not_AE_Candidate
- I-Not_AE_Candidate
sigmoid I-Not_AE_Candidate
involvement I-Not_AE_Candidate
by O
pelvic O
examination O
or O
bowel B-Not_AE_Candidate
involvement I-Not_AE_Candidate
on O
CT O
scan O
or O
clinical O
symptoms O
of O
bowel B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Discontinue O
in O
patients O
who O
develop O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
, O
tracheoesophageal B-NonOSE_AE
fistula I-NonOSE_AE
or O
any O
Grade O
4 O
fistula B-NonOSE_AE
. O

Discontinue O
in O
patients O
with O
fistula B-NonOSE_AE
formation I-NonOSE_AE
involving I-NonOSE_AE
any I-NonOSE_AE
internal I-NonOSE_AE
organ I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Surgery O
and O
Wound O
Healing O
Complications O
In O
a O
controlled O
clinical O
study O
in O
which O
Avastin O
was O
not O
administered O
within O
28 O
days O
of O
major O
surgical O
procedures O
, O
the O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
including O
serious O
and O
fatal B-NonOSE_AE
complications O
, O
was O
15 O
% O
in O
patients O
with O
mCRC B-Not_AE_Candidate
who O
underwent O
surgery O
while O
receiving O
Avastin O
and O
4 O
% O
in O
patients O
who O
did O
not O
receive O
Avastin O
. O

In O
a O
controlled O
clinical O
study O
in O
patients O
with O
relapsed O
or O
recurrent O
GBM B-Not_AE_Candidate
, O
the O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
5 O
% O
in O
patients O
who O
received O
Avastin O
and O
0.7 O
% O
in O
patients O
who O
did O
not O
receive O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Discontinue O
Avastin O
in O
patients O
with O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
requiring O
medical O
intervention O
. O

Withhold O
for O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
for O
at O
least O
28 O
days O
following O
surgery O
and O
until O
the O
wound O
is O
fully O
healed O
. O

Necrotizing B-OSE_Labeled_AE
fasciitis I-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
cases O
, O
has O
been O
reported O
in O
patients O
receiving O
Avastin O
, O
usually O
secondary O
to O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
or O
fistula B-OSE_Labeled_AE
formation O
. O

Discontinue O
in O
patients O
who O
develop O
necrotizing B-NonOSE_AE
fasciitis I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

5.3 O
Hemorrhage O
Avastin O
can O
result O
in O
two O
distinct O
patterns O
of O
bleeding B-OSE_Labeled_AE
: O
minor O
hemorrhage B-OSE_Labeled_AE
, O
most O
commonly O
Grade O
1 O
epistaxis B-OSE_Labeled_AE
; O
and O
serious O
, O
and O
in O
some O
cases O
fatal B-NonOSE_AE
, O
hemorrhage B-OSE_Labeled_AE
. O

Severe O
or O
fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
, O
including O
hemoptysis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
CNS B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
vaginal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
occurred O
up O
to O
5-fold O
more O
frequently O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
alone O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grades O
3-5 O
hemorrhagic B-OSE_Labeled_AE
events O
ranged O
from O
0.4 O
% O
to O
7 O
% O
in O
patients O
receiving O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Serious O
or O
fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
occurred O
in O
31 O
% O
of O
patients O
with O
squamous O
NSCLC B-Not_AE_Candidate
and O
4 O
% O
of O
patients O
with O
non-squamous O
NSCLC B-Not_AE_Candidate
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
none O
of O
the O
patients O
receiving O
chemotherapy O
alone O
. O

Do O
not O
administer O
Avastin O
to O
patients O
with O
recent O
history O
of O
hemoptysis B-Not_AE_Candidate
of O
1/2 O
teaspoon O
or O
more O
of O
red O
blood O
. O

Discontinue O
in O
patients O
who O
develop O
a O
Grade O
3-4 O
hemorrhage B-NonOSE_AE
. O

5.4 O
Arterial O
Thromboembolic O
Events O
Serious O
, O
sometimes O
fatal B-NonOSE_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATE I-OSE_Labeled_AE
) O
including O
cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
angina B-OSE_Labeled_AE
, O
occurred O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grades O
3-5 O
ATE O
was O
5 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
< O
= O
2 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
; O
the O
highest O
incidence O
occurred O
in O
patients O
with O
GBM B-Not_AE_Candidate
. O

The O
risk O
of O
developing O
ATE B-NonOSE_AE
was O
increased O
in O
patients O
with O
a O
history O
of O
arterial B-Not_AE_Candidate
thromboembolism I-Not_AE_Candidate
, O
diabetes B-Not_AE_Candidate
, O
or O
greater O
than O
65 O
years O
old O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Discontinue O
in O
patients O
who O
develop O
a O
severe O
ATE B-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
Avastin O
after O
an O
ATE B-NonOSE_AE
is O
resolved O
is O
not O
known O
. O

5.5 O
Venous O
Thromboembolic O
Events O
An O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VTE I-OSE_Labeled_AE
) O
was O
observed O
across O
clinical O
studies O
. O

In O
Study O
GOG-0240 O
, O
Grade O
3-4 O
VTE B-OSE_Labeled_AE
was O
reported O
in O
11 O
% O
of O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
with O
5 O
% O
of O
patients O
receiving O
chemotherapy O
alone O
. O

In O
EORTC O
26101 O
, O
the O
incidence O
of O
Grade O
3-4 O
VTE B-OSE_Labeled_AE
was O
5 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
2 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
. O

Discontinue O
Avastin O
in O
patients O
with O
a O
Grade O
4 O
VTE B-NonOSE_AE
, O
including O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Hypertension O
The O
incidence O
of O
severe O
hypertension B-OSE_Labeled_AE
is O
increased O
in O
patients O
receiving O
Avastin O
as O
compared O
to O
patients O
receiving O
chemotherapy O
alone O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
ranged O
from O
5 O
% O
to O
18 O
% O
. O

Monitor O
blood O
pressure O
every O
two O
to O
three O
weeks O
during O
treatment O
with O
Avastin O
. O

Treat O
with O
appropriate O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
monitor O
blood O
pressure O
regularly O
. O

Continue O
to O
monitor O
blood O
pressure O
at O
regular O
intervals O
in O
patients O
with O
Avastin-induced O
or O
-exacerbated O
hypertension B-NonOSE_AE
after O
discontinuing O
Avastin O
. O

Withhold O
Avastin O
in O
patients O
with O
severe O
hypertension B-NonOSE_AE
that O
is O
not O
controlled O
with O
medical O
management O
; O
resume O
once O
controlled O
with O
medical O
management O
. O

Discontinue O
in O
patients O
who O
develop O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
. O

5.7 O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
PRES B-OSE_Labeled_AE
was O
reported O
in O
< O
0.5 O
% O
of O
patients O
across O
clinical O
studies O
. O

The O
onset O
of O
symptoms O
occurred O
from O
16 O
hours O
to O
1 O
year O
after O
the O
first O
dose O
. O

PRES B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

Magnetic O
resonance O
imaging O
is O
necessary O
to O
confirm O
the O
diagnosis O
of O
PRES B-NonOSE_AE
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
PRES B-NonOSE_AE
. O

Symptoms O
usually O
resolve O
or O
improve O
within O
days O
after O
discontinuing O
Avastin O
, O
although O
some O
patients O
have O
experienced O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
Avastin O
in O
patients O
who O
developed O
PRES B-NonOSE_AE
is O
not O
known O
. O

5.8 O
Renal B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Proteinuria O
The O
incidence O
and O
severity O
of O
proteinuria B-OSE_Labeled_AE
is O
higher O
in O
patients O
receiving O
Avastin O
as O
compared O
to O
patients O
receiving O
chemotherapy O
. O

Grade O
3 O
( O
defined O
as O
urine B-OSE_Labeled_AE
dipstick I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
or I-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
grams I-OSE_Labeled_AE
of I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
per I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
hours I-OSE_Labeled_AE
) O
to O
Grade O
4 O
( O
defined O
as O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
ranged O
from O
0.7 O
% O
to O
7 O
% O
in O
clinical O
studies O
. O

The O
overall O
incidence O
of O
proteinuria B-OSE_Labeled_AE
( O
all O
grades O
) O
was O
only O
adequately O
assessed O
in O
Study O
BO17705 O
, O
in O
which O
the O
incidence O
was O
20 O
% O
. O

Median O
onset O
of O
proteinuria B-OSE_Labeled_AE
was O
5.6 O
months O
( O
15 O
days O
to O
37 O
months O
) O
after O
initiating O
Avastin O
. O

Median O
time O
to O
resolution O
was O
6.1 O
months O
( O
95 O
% O
CI O
: O
2.8 O
, O
11.3 O
) O
. O

Proteinuria B-OSE_Labeled_AE
did O
not O
resolve O
in O
40 O
% O
of O
patients O
after O
median O
follow-up O
of O
11.2 O
months O
and O
required O
discontinuation O
of O
Avastin O
in O
30 O
% O
of O
the O
patients O
who O
developed O
proteinuria B-OSE_Labeled_AE
. O

In O
an O
exploratory O
, O
pooled O
analysis O
of O
patients O
from O
seven O
randomized O
clinical O
studies O
, O
5 O
% O
of O
patients O
receiving O
Avastin O
with O
chemotherapy O
experienced O
Grades O
2-4 O
( O
defined O
as O
urine B-OSE_Labeled_AE
dipstick I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
or I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
or I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
gram I-OSE_Labeled_AE
of I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
per I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
hours I-OSE_Labeled_AE
or O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
proteinuria B-OSE_Labeled_AE
. O

Grades O
2-4 O
proteinuria B-OSE_Labeled_AE
resolved O
in O
74 O
% O
of O
patients O
. O

Avastin O
was O
reinitiated O
in O
42 O
% O
of O
patients O
. O

Of O
the O
113 O
patients O
who O
reinitiated O
Avastin O
, O
48 O
% O
experienced O
a O
second O
episode O
of O
Grade O
2-4 O
proteinuria B-OSE_Labeled_AE
. O

Nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
of O
patients O
receiving O
Avastin O
across O
clinical O
studies O
, O
in O
some O
instances O
with O
fatal B-NonOSE_AE
outcome O
. O

In O
a O
published O
case O
series O
, O
kidney O
biopsy O
of O
6 O
patients O
with O
proteinuria B-OSE_Labeled_AE
showed O
findings O
consistent O
with O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
. O

Results O
of O
a O
retrospective O
analysis O
of O
5805 O
patients O
who O
received O
Avastin O
with O
chemotherapy O
and O
3713 O
patients O
who O
received O
chemotherapy O
alone O
, O
showed O
higher O
rates O
of O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
between O
1.5 O
to O
1.9 O
times O
baseline O
levels O
) O
in O
patients O
who O
received O
Avastin O
. O

Serum O
creatinine O
levels O
did O
not O
return O
to O
baseline O
in O
approximately O
one-third O
of O
patients O
who O
received O
Avastin O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
dipstick O
urine O
analysis O
for O
the O
development O
or O
worsening O
of O
proteinuria B-NonOSE_AE
with O
serial O
urinalyses O
during O
Avastin O
therapy O
. O

Patients O
with O
a O
2+ O
or O
greater O
urine O
dipstick O
reading O
should O
undergo O
further O
assessment O
with O
a O
24-hour O
urine O
collection O
. O

Withhold O
for O
proteinuria B-NonOSE_AE
greater O
than O
or O
equal O
to O
2 O
grams O
per O
24 O
hours O
and O
resume O
when O
less O
than O
2 O
grams O
per O
24 O
hours O
. O

Discontinue O
in O
patients O
who O
develop O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Data O
from O
a O
postmarketing O
safety O
study O
showed O
poor O
correlation O
between O
UPCR O
( O
Urine O
Protein/Creatinine O
Ratio O
) O
and O
24-hour O
urine O
protein O
[ O
Pearson O
Correlation O
0.39 O
( O
95 O
% O
CI O
: O
0.17 O
, O
0.57 O
) O
] O
. O

5.9 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
reported O
across O
clinical O
studies O
and O
post-marketing O
experience O
include O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crises I-OSE_Labeled_AE
associated O
with O
neurologic B-OSE_Labeled_AE
signs I-OSE_Labeled_AE
and I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
Grade O
3 O
hypersensitivity B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
headaches B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
and O
diaphoresis B-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
with O
the O
first O
dose O
occurred O
in O
< O
3 O
% O
of O
patients O
and O
severe O
reactions O
occurred O
in O
0.2 O
% O
of O
patients O
. O

Decrease O
the O
rate O
of O
infusion O
for O
mild O
, O
clinically O
insignificant O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Interrupt O
the O
infusion O
in O
patients O
with O
clinically O
significant O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
and O
consider O
resuming O
at O
a O
slower O
rate O
following O
resolution O
. O

Discontinue O
in O
patients O
who O
develop O
a O
severe O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
and O
administer O
appropriate O
medical O
therapy O
( O
e.g. O
, O
epinephrine O
, O
corticosteroids O
, O
intravenous O
antihistamines O
, O
bronchodilators O
and/or O
oxygen O
) O
. O

5.10 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Avastin O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
based O
on O
its O
mechanism O
of O
action O
and O
findings O
from O
animal O
studies O
. O

Congenital B-NonOSE_AE
malformations I-NonOSE_AE
were O
observed O
with O
the O
administration O
of O
bevacizumab O
to O
pregnant B-NonOSE_AE
rabbits O
during O
organogenesis O
every O
3 O
days O
at O
a O
dose O
as O
low O
as O
a O
clinical O
dose O
of O
10 O
mg/kg O
. O

Furthermore O
, O
animal O
models O
link O
angiogenesis O
and O
VEGF O
and O
VEGFR O
2 O
to O
critical O
aspects O
of O
female O
reproduction O
, O
embryo-fetal O
development O
, O
and O
postnatal O
development O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
and O
for O
6 O
months O
after O
the O
last O
dose O
of O
Avastin O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
, O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

5.11 O
Ovarian O
Failure O
The O
incidence O
of O
ovarian B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
34 O
% O
vs O
. O
2 O
% O
in O
premenopausal B-Not_AE_Candidate
women O
receiving O
Avastin O
with O
chemotherapy O
as O
compared O
to O
those O
receiving O
chemotherapy O
alone O
for O
adjuvant O
treatment O
of O
a O
solid O
tumor B-Not_AE_Candidate
. O

After O
discontinuing O
Avastin O
, O
recovery O
of O
ovarian O
function O
at O
all O
time O
points O
during O
the O
post-treatment O
period O
was O
demonstrated O
in O
22 O
% O
of O
women O
receiving O
Avastin O
. O

Recovery O
of O
ovarian O
function O
is O
defined O
as O
resumption O
of O
menses O
, O
a O
positive B-NonOSE_AE
serum I-NonOSE_AE
beta I-NonOSE_AE
- I-NonOSE_AE
HCG I-NonOSE_AE
pregnancy I-NonOSE_AE
test I-NonOSE_AE
, O
or O
a O
FSH O
level O
< O
30 O
mIU/mL O
during O
the O
post-treatment O
period O
. O

Long-term O
effects O
of O
Avastin O
on O
fertility O
are O
unknown O
. O

Inform O
females O
of O
reproductive O
potential O
of O
the O
risk O
of O
ovarian B-NonOSE_AE
failure I-NonOSE_AE
prior O
to O
initiating O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

5.12 O
Congestive O
Heart O
Failure O
( O
CHF O
) O
Avastin O
is O
not O
indicated O
for O
use O
with O
anthracycline-based O
chemotherapy O
. O

The O
incidence O
of O
Grade O
> O
= O
3 O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
1 O
% O
in O
patients O
receiving O
Avastin O
compared O
to O
0.6 O
% O
of O
patients O
receiving O
chemotherapy O
alone O
. O

Among O
patients O
who O
received O
prior O
anthracycline O
treatment O
, O
the O
rate O
of O
CHF B-NonOSE_AE
was O
4 O
% O
for O
patients O
receiving O
Avastin O
with O
chemotherapy O
as O
compared O
to O
0.6 O
% O
for O
patients O
receiving O
chemotherapy O
alone O
. O

In O
previously O
untreated O
patients O
with O
a O
hematological B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
, O
the O
incidence O
of O
CHF B-NonOSE_AE
and O
decline B-NonOSE_AE
in I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
ejection I-NonOSE_AE
fraction I-NonOSE_AE
( I-NonOSE_AE
LVEF I-NonOSE_AE
) O
were O
increased O
in O
patients O
receiving O
Avastin O
with O
anthracycline-based O
chemotherapy O
compared O
to O
patients O
receiving O
placebo O
with O
the O
same O
chemotherapy O
regimen O
. O

The O
proportion O
of O
patients O
with O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
from O
baseline O
of O
> O
= O
20 O
% O
or O
a O
decline O
from O
baseline O
of O
10 O
% O
to O
< O
50 O
% O
, O
was O
10 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
5 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
. O

Time O
to O
onset O
of O
left B-NonOSE_AE
- I-NonOSE_AE
ventricular I-NonOSE_AE
dysfunction I-NonOSE_AE
or O
CHF B-NonOSE_AE
was O
1 O
to O
6 O
months O
after O
the O
first O
dose O
in O
at O
least O
85 O
% O
of O
the O
patients O
and O
was O
resolved O
in O
62 O
% O
of O
the O
patients O
who O
developed O
CHF B-NonOSE_AE
in O
the O
Avastin O
arm O
compared O
to O
82 O
% O
in O
the O
placebo O
arm O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
CHF B-NonOSE_AE
. O

